Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
Istituto Europeo di Microchirurgia Oculare · University of Udine · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
209
total citations
- FWCI
- 100.56
- Percentile
- 100%
- References
- 28
Citations per year
Authors
24- PLPaolo Lanzetta
Istituto Europeo di Microchirurgia Oculare, University of Udine
- JKJean‐François Korobelnik
Inserm, Centre Hospitalier Universitaire de Bordeaux, Bordeaux Population Health, Université de Bordeaux
- JSJeffrey S. HeierCorresponding
Ophthalmic Consultants of Boston
- SLSérgio Leal
Bayer (Switzerland)
- FGFrank G. Holz
University of Bonn
Topics & keywords
Topics
Keywords
- Aflibercept
- Medicine
- Macular degeneration
- Dosing
- Visual acuity
- Clinical endpoint
- Ophthalmology
- Randomized controlled trial
UN Sustainable Development Goals
- Gender equality
No related works found for this paper.